It was lovely to meet with Dr Bruno Sangro (Clínica Universidad de Navarra, Pamplona, Spain) to talk about some of the early phase data presented at EASL 2021 around immune checkpoint inhibitors in the treatment of HCC.
- Why are patients with Child-Pugh B liver function excluded from clinical trials, and what is their prognosis? (0:11)
- What has the CheckMate 040 Cohort 5 study taught us about the clinical impact of nivolumab in these patients? (1:04)
- What did we learn from this meeting about the efficacy and safety of hepatic arterial infusion chemotherapy in combination with sintilimab? (2:32)
- Which of the advances in immune checkpoint inhibitors do you consider to be particularly promising? (4:03)
Disclosures: Dr Bruno Sangro has received consultancy and/ or speaker fees from Adaptimmune, AstraZeneca, Bayer, BMS, Boston Scientific, BTG, Eli Lilly, Ipsen, Roche, Sirtex and Terumo; and research grants (to Institution) from BMS and Sirtex.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the EASL ILC 2021, 23-26 June.
Share this Video
Related Videos In Gastrointestinal Oncology
Angela Lamarca, ESMO 2022: ABC-06 trial, quality of life results – Symptom-control with FOLFOX in the treatment of advanced biliary cancers
The ABC-06 clinical trial established active-symptom control + oxaliplatin/5-FU chemotherapy (FOLFOX) as the standard of care treatment after Cisplatin and Gemcitabine for advanced biliary cancers. Dr Angela Lamarca (Fundación Jiménez Diaz University Hospital, Madrid, Spain) joins touchONCOLOGY to discuss the efficacy and safety of second-line active- symptom-control with FOLFOX, and the quality of life and […]
Alvaro Arjona-Sanchez, ESMO 2022: HIPECT4 phase 3 trial investigating the efficacy and safety of adjuvant HIPEC in patients with locally advanced colon cancer
Peritoneal metastasis in locally advanced colon cancer has a poor prognosis from 3 years post surgical resection. Dr Alvaro Arjona-Sanchez (Institute of Biomedical Research IMIBIC, University Hospital Reina Sofia, Cordoba, Spain) joins touchONCOLOGY to discuss the HIPECT4 phase 3 trial investigating the efficacy and safety of adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with locally […]
Myriam Chalabi, ESMO 2022: Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: the NICHE-2 study
Neoadjuvant immunotherapy has shown promising responses in several cancer types. In this touchONCOLOGY interview Dr Myriam Chalabi (Netherlands Cancer Institute, Amsterdam, Netherlands) discusses the NICHE-2 study results, investigating patients with non-metastatic deficient DNA mismatch repair (dMMR) colon cancer, treated with one dose of ipilimumab and two doses of nivolumab and underwent surgery ≤6 weeks of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!